Biovie (BIVI) Amortizatization of Intangibles (2017 - 2024)
Biovie (BIVI) posted Amortizatization of Intangibles of $2364.0 for Q4 2024, down 75.0% sequentially from $9456.0 in Q3 2024, and down 92.31% YoY from $30735.0 in Q1 2024.
Biovie (BIVI) Amortizatization of Intangibles (2017 - 2024) Analysis & Trends
Biovie has reported Amortizatization of Intangibles for 5 years, with the latest figure at $2364.0 in Q4 2024.
- Quarterly Amortizatization of Intangibles fell 92.31% year-over-year to $2364.0 in Q4 2024, while the trailing twelve-month figure through Jun 2025 was $11820.0 (down 89.13% YoY) and the FY2025 annual result came in at $11820.0, down 89.13% from the prior year.
- Amortizatization of Intangibles eased to $2364.0 in Q4 2024 per BIVI's latest filing, from $9456.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $798889.0 in Q1 2024 and troughed at -$758698.0 in Q2 2024.
- A 3-year average of $32507.2 and a median of $42554.5 in 2022 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 1777.35% in 2024, down 1882.86% in 2024.
- Over 3 years, Amortizatization of Intangibles stood at $42556.0 in 2022, then dropped by 27.78% to $30735.0 in 2023, then slumped by 92.31% to $2364.0 in 2024.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $2364.0, $9456.0, and -$758698.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2,364.00 |
| Dec 31, 2024 | 2,364.00 |
| Sep 30, 2024 | 9,456.00 |
| Sep 30, 2024 | 9,456.00 |
| Jun 30, 2024 | -758,698.00 |
| Jun 30, 2024 | -758,698.00 |
| Mar 31, 2024 | 798,889.00 |
| Mar 31, 2024 | 798,889.00 |
| Dec 31, 2023 | 30,735.00 |
| Dec 31, 2023 | 30,735.00 |
| Sep 30, 2023 | 37,825.00 |
| Sep 30, 2023 | 37,825.00 |
| Jun 30, 2023 | 42,555.00 |
| Jun 30, 2023 | 42,555.00 |
| Mar 31, 2023 | 42,554.00 |
| Mar 31, 2023 | 42,554.00 |
| Dec 31, 2022 | 42,556.00 |
| Dec 31, 2022 | 42,556.00 |
| Sep 30, 2022 | 56,740.00 |
| Sep 30, 2022 | 56,740.00 |